Map Collaborator Decision Roles in a Shared Research Evaluation

A shared research evaluation with multiple principal investigators rarely fails because the science is unclear. It fails because nobody agrees on who decides what, and the account executive who asks that question early keeps the deal moving while everyone else waits for someone to raise their hand.

Why This Conversation Goes Wrong

When several investigators evaluate a platform or service together, each one has a different stake in the outcome. One cares about workflow fit. Another cares about data output format. A third cares about turnaround time. None of them owns the purchasing decision, and often none of them owns the local access decision either. The account executive who treats this group as a single buying committee ends up presenting the same material five times, scheduling meetings nobody can attend, and mistaking enthusiasm from one investigator for approval from the group.

The deeper problem is that research organizations split authority across roles that rarely meet in the same room. A principal investigator can approve scientific relevance but cannot approve a purchase order. A core facility director can approve operational capacity but has no say in which vendor a lab prefers. Procurement can approve a purchasing route but will not evaluate the science at all. If you don't map these roles early, you spend your time managing confusion instead of managing a sale, and you risk quoting or demonstrating to someone who cannot move the process forward on their own. This same pattern shows up when things go wrong partway through an evaluation, not just at the start. See Coordinate an Account Communication Escalation During a Research Disruption for how role clarity helps when a disruption forces you to loop in the right people fast.

How To Prepare

Before you sit down with any collaborator, write out what you already know about the evaluation. List the labs involved, the core facility if one is in play, and any procurement or purchasing contact you have worked with before. Then mark what you do not know. Most gaps involve the connective tissue between roles, not the roles themselves. You probably know who the lead investigator is. You probably do not know whether the group needs to reach a joint scientific recommendation before procurement will open an intake process, or whether each lab can move independently once its own review clears.

Prepare two or three direct questions you can ask the person who called the meeting. Ask what the group must decide together and what each lab can decide on its own. Ask who receives the final recommendation once the scientific review finishes. Ask whether a procurement or access review runs in parallel with the scientific evaluation or only starts after it. Write these questions down. In the moment, it is easy to let a contact talk about the science for twenty minutes and leave without the one answer you actually needed.

What To Say

Marcus, a translational program lead at a fictional institute, opens the call with a familiar complaint. He says, "Four principal investigators want to compare approaches, and I cannot get them to agree on a next meeting."

You do not try to solve the scheduling problem first. You ask, "What does the group need to decide together, and what stays inside each lab?"

Marcus thinks about it and answers, "The investigators each judge whether the workflow fits their own project. The core facility looks at whether they can support it operationally. Procurement decides the actual purchasing route once everyone signs off."

You follow with the question that turns this into something you can act on. "Once the scientific review wraps up, who confirms the process moves forward, and who owns that decision on your side?"

Marcus names the core facility director as the person who signs off on operational readiness, and confirms that procurement only opens an intake once that sign off is on record. Now you have a sequence instead of four disconnected conversations. You know to keep the investigators focused on workflow evidence, bring the core facility director in once that evidence is ready, and hold procurement until the operational sign off exists.

Turn this into a simple decision map with three columns, the decision itself, who contributes evidence, and who owns the final call. Put a date next to any decision that gates the rest of the evaluation, such as a local access review or a procurement intake window. Share a plain version of this map back with Marcus so he can correct anything you got wrong. That single step often surfaces a role you missed, like a department chair who has to approve budget before procurement will engage.

Mistakes To Avoid

Do not send the same detailed technical package to every investigator and hope one of them is the decision maker. That wastes their time and yours, and it signals you have not done the work of understanding their process. Do not treat a demonstration that goes well with one investigator as a signal that the group has decided. Enthusiasm from a single lab is evidence, not a decision.

Do not skip the question of sequence. Knowing that the core facility and procurement both matter is not the same as knowing which one acts first. If you invite procurement into a conversation before the scientific review is done, you either bore them with material they cannot act on yet or you push them to make a call they are not ready to make, and either one costs you credibility.

Do not assume the map you draw in week one still holds in week six. Staff changes, budget cycles close, and a core facility director who owned the decision in your first call might hand it off once the workload increases. Check the map again whenever a new person joins the conversation or a timeline shifts.

If a consumable or reagent substitution question comes up during the evaluation, keep it separate from the decision map conversation and route it through the approved process, which you can review in Handle a Consumable Substitution Question Through Approved Options.

How To Practice And Score It

Pick one active account and draw the decision map from memory, before you check your notes. Write down every decision you think the account needs to make, who you believe contributes evidence for each one, and who you believe owns the final call. Then compare your version against your actual meeting notes and correct any gaps.

A manager can score this exercise on three things. First, did you separate the decisions that need group agreement from the decisions that stay inside a single lab. Second, did you identify a specific owner for each decision rather than a vague group like the committee. Third, did you ask a direct follow up question when ownership was unclear instead of guessing or letting the ambiguity sit. A rep who guesses at ownership will eventually present the wrong material to the wrong person, and that mistake is expensive to walk back.

You can rehearse the live version of this conversation too. Practice asking the sequencing question, what happens after the scientific review, out loud until it feels natural rather than scripted. DealSpeak's Biotechnology practice conversations let you run this exact exchange with an AI counterpart playing a program lead like Marcus, and you get scored on whether you actually pinned down the decision sequence or just collected more scientific opinions. Running the scenario a few times before a real account call builds the habit of asking for the owner before you ask for the meeting.

Close

Mapping decision roles is not extra process. It is the difference between managing a sale and managing confusion. Ask who decides, capture the answer in your account record, and bring each owner into the conversation only when their piece of the decision is actually ready.